Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
5.045
+0.18
(+3.81%)
USD |
NASDAQ |
Oct 26, 16:00
5.14
+0.10
(+1.88%)
After-Hours: 20:00
Shuttle Pharmaceuticals Holdings Enterprise Value : 5.156M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 5.156M |
| October 23, 2026 | 4.971M |
| October 22, 2026 | 4.720M |
| October 21, 2026 | 4.931M |
| October 20, 2026 | 5.021M |
| October 19, 2026 | 4.831M |
| October 16, 2026 | 5.191M |
| October 15, 2026 | 5.682M |
| October 14, 2026 | 5.351M |
| October 13, 2026 | 5.291M |
| October 12, 2026 | 5.562M |
| October 09, 2026 | 5.441M |
| October 08, 2026 | 5.662M |
| October 07, 2026 | 4.821M |
| October 06, 2026 | 4.170M |
| October 05, 2026 | 4.120M |
| October 02, 2026 | 4.28M |
| October 01, 2026 | 4.060M |
| September 30, 2026 | 4.150M |
| September 29, 2026 | 4.030M |
| September 28, 2026 | 4.220M |
| September 25, 2026 | 4.120M |
| September 24, 2026 | 4.110M |
| September 23, 2026 | 3.699M |
| September 22, 2026 | 3.870M |
| Date | Value |
|---|---|
| September 21, 2026 | 3.579M |
| September 18, 2026 | 3.319M |
| September 17, 2026 | 3.489M |
| September 16, 2026 | 3.239M |
| September 15, 2026 | 3.639M |
| September 14, 2026 | 3.559M |
| September 11, 2026 | 3.639M |
| September 10, 2026 | 3.639M |
| September 09, 2026 | 3.609M |
| September 08, 2026 | 3.649M |
| September 04, 2026 | 3.609M |
| September 03, 2026 | 3.589M |
| September 02, 2026 | 3.599M |
| September 01, 2026 | 3.719M |
| August 31, 2026 | 3.469M |
| August 28, 2026 | 3.649M |
| August 27, 2026 | 3.990M |
| August 26, 2026 | 3.699M |
| August 25, 2026 | 3.549M |
| August 24, 2026 | 3.629M |
| August 21, 2026 | 3.870M |
| August 20, 2026 | 3.820M |
| August 19, 2026 | 3.870M |
| August 18, 2026 | 4.030M |
| August 17, 2026 | 4.210M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.515B |
| Alnylam Pharmaceuticals, Inc. | 30.13B |
| Anika Therapeutics, Inc. | 271.49M |
| Savara, Inc. | 785.78M |
| Vericel Corp. | 2.135B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.146M |
| Total Expenses (Quarterly) | 3.146M |
| EPS Diluted (Quarterly) | -3.098 |
| Earnings Yield | -610.6% |
| Normalized Earnings Yield | -632.99 |